100 likes | 111 Views
Best Cure of Allergy in Jaipur and Covid-19 treatment by Dr. Nishtha Singh
E N D
FDA: You Can Use Chloroquine to Treat COVID-19; EU Regulators: Not Just Yet
Updated :April 01. 2020 07:05 AM IST Healthcare • Indian government/ ICMR approves hydroxychloroquine (Dose 400mg BD –for 1 day followed by 200mg BD for 4 days) + azithromycin (500mg OD for 5 days) for critical COVID-19 patients
Chemoprophylaxis • Recommended for 2 high risk groups • 1) Asymptomatic health care workers involved in treating confirmed or suspected COVID-19 patients • Dose: 400mg twice a day on Day1,followed by 400mg once weekly for next 7 weeks • 2) Asymptomatic household contacts of laboratory confirmed cases • Dose:400mg twice a day on Day1, followed by 400mg once weekly for next 3 weeks
Chloroquine/Hydroxychloroquine Prevention of coronavirus disease (COVID-19) in the Healthcare setting; a Randomised, placebo-controlled Prophylaxis study (COPCOV)
My take on the HCQS story - - • HCQS FOR TREATMENT • Considering the dire situation we are in with: • No other drugs options • No vaccine in sight, • Relatively good safety profile • IT MAY BE REASONABLE TO USE HCQS FOR SYMPTOMATIC PATIENTS HCQS FOR PROPHYLAXIS Data even more scanty ICMR recommended Dose of once a week seems neither here nor there INDIVIDUAL DECISION?
Jak inhibitors/Baricitinib MOA- The receptors of novel coronavirus pneumonia (2019-nCoV), might be ACE2, which is a cell-surface protein widely existed on cells in the heart, kidney, blood vessels, especially alveolar epithelial cells. 2019-nCoV could invade and enter cells through endocytosis. One of the known regulators of endocytosis is the AP2-associated protein kinase 1 (AAK1). AAK1 inhibitors can interrupt the passage of the virus into cells and can be helpful in preventing virus infections. Baricitinib, a JAK inhibitor as well as an AAK1 inhibitor, was suggested a possible candidate for treatment of COVID-19, considering its relative safety and high: “Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)
The role of Convalescent plasma in treatment of SARS COVID 19
Plasma Plasma cells collected from donors who have recovered from COVID-19. These cells contain antibodies that can help the body protect itself from coronavirus. Dose :- One unit of COVID-19 Convalescent Plasma of High Titer
Convalescent plasma: background • 2014: Recommended as an empirical treatment during the Ebola outbreak • 2015: A protocol for treatment of MERS coronavirus was established • Also considered effective in other viral infection: SARS-CoV1, H5N1 avian influenza, and H1N1 influenza